MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.

Based on mutation screening and results from 2SC immunohistochemistry, the difference in MED12 mutation and biallelic FH inactivation frequencies between uterine leiomyomas from HLRCC patients and sporadic conventional uterine leiomyomas is highly significant ( P <2.2 × 10 −16 ).

also in 132,142 other papers